Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | COMT | P21964 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9915399 | 0.77 | TYR (0.53) | TYRCOMT | |
| SCHEMBL23139408 | 0.76 | APP (0.45) | TYRAPPCOMT | |
| SCHEMBL15100202 | 0.74 | APP (0.44) | TYRAPP | |
| SCHEMBL16882309 | 0.72 | TYR (0.72) | TYRCOMT | |
| SCHEMBL11926716 | 0.72 | TYR (0.49) | TYRAPPCOMT | |
| SCHEMBL15991636 | 0.72 | CCNC (0.49) | TYRAPP | |
| SCHEMBL7931821 | 0.72 | COMT (0.56) | TYRAPPCOMT | |
| SCHEMBL19331472 | 0.72 | TYR (0.49) | TYRCOMT | |
| SCHEMBL20524630 | 0.72 | ALDH1A1 (0.57) | TYR | |
| SCHEMBL9012839 | 0.72 | APP (0.42) | TYRAPPCOMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| EP-0093498-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING N-SUBSTITUTED-3-HYDROXYPYRID-2-ONE OR -4-ONE DERIVATIVES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-11-26 | — | — | EP | claimed |
| EP-0093498-A2 | Pharmaceutical compositions containing N-substituted-3-hydroxypyrid-2-one or -4-one derivatives | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-11-09 | — | — | EP | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | disclosed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | disclosed |
| US-10889556-B2 | Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190106398-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-04-11 | — | — | US | disclosed |
| US-20170291971-A1 | FUNCTIONAL POLYMER | SUSOS AG (CH) | 2017-10-12 | — | — | US | disclosed |
| WO-2017156194-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-09-14 | — | — | WO | disclosed |
| US-8026261-B2 | neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one | APOTEX TECHNOLOGIES INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2010-03-04 | — | — | US | disclosed |
| EP-2134688-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | Apotex Technologies Inc. (CA) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008116301-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. | 2008-10-02 | — | — | US | disclosed |
| US-4840958-A | Novel 3-hydroxypyrid-2-ones and 3-hydroxyprid-4-ones useful in treating patients having a toxic concentration of iron | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1989-06-20 | — | — | US | disclosed |
| EP-0093498-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING N-SUBSTITUTED-3-HYDROXYPYRID-2-ONE OR -4-ONE DERIVATIVES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-11-26 | — | — | EP | disclosed |
| EP-0093498-A2 | Pharmaceutical compositions containing N-substituted-3-hydroxypyrid-2-one or -4-one derivatives | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106398-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE | POLRMT, RNASE1, POLM | TYR 2571/4885APP 3299/4885COMT 2088/4885 |
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | SLC40A1, TFRC, FECH | TYR 1743/4885APP 138/4885COMT 695/4885 |
| US-10889556-B2 | Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease | POLRMT, RNASE1, POLM | TYR 2571/4885APP 3299/4885COMT 2088/4885 |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | MGAM, MGAM2, B2M | TYR 4381/4885APP 2588/4885COMT 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.